On December 10, 2020, Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, announced an additional $200 million financing at a post-money valuation of $8.1 billion, and an additional $250 million of convertible debt. The investors include Baillie Gifford, Franklin Templeton, Google, Novo Holdings, and funds and accounts managed by T. Rowe Price. Wilson Sonsini Goodrich & Rosati is advising Novo Holdings in the transaction.
According to the press release, the company is using the additional funds to expand its operations and establish its work with other disease areas, including infectious diseases, depression, and cardiology. With these investments, Tempus has now raised around $1.05 billion.
The Wilson Sonsini team advising Novo Holdings includes partners Dan Koeppen and Stephen Heifetz, and associates Meghan Burton and John Lynch.
Please see Tempus’ press release for more information.